Connect with us


More Covid-19 Vaccines on the Market as Glaxo, SK Bioscience Start Final Testing of Covid-19 Vaccine



Good news to the fight against Covid-19 as GlaxoSmithKline Plc said it’s starting a final stage clinical trial on a Covid-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co.

The study will enroll 4,000 participants and compare the shot to that of AstraZeneca Plc and Oxford University, Glaxo said Tuesday. The U.K. drugmaker is providing an adjuvant, which is a substance that can enhance the response to vaccines.


Sign up for our Newsletter

Enter your email and stay on top of things,